<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys	</title>
	<atom:link href="https://www.novumpr.nl/2018/03/05/gilead-announces-data-from-new-preclinical-study-evaluating-a-combination-of-an-investigational-tlr7-agonist-and-an-investigational-hiv-envelope-targeting-antibody-in-shiv-infected-virally-suppressed/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2018/03/05/gilead-announces-data-from-new-preclinical-study-evaluating-a-combination-of-an-investigational-tlr7-agonist-and-an-investigational-hiv-envelope-targeting-antibody-in-shiv-infected-virally-suppressed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-announces-data-from-new-preclinical-study-evaluating-a-combination-of-an-investigational-tlr7-agonist-and-an-investigational-hiv-envelope-targeting-antibody-in-shiv-infected-virally-suppressed</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Mon, 05 Mar 2018 10:31:34 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
